Engimmune Therapeutics AG
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Engimmune Therapeutics AG - overview
Established
2021
Location
Basel, -, Switzerland
Primary Industry
Biotechnology
About
In 2021, the company was co-founded by Dr. Rodrigo Vazquez-Lombardii, who serves as the company CSO, Prof. Sai Reddy, who serves as Chairman of the Scientific Advisory Board (SAB), and Dr. Søren Mouritsen, who serves as the CEO of the company.
In 2022, the company raised USD 16 million co-led by Pureos Bioventures and Novo Holdings. Along with this financing, the board appointed two investors Dr. Dominik Escher (Pureos) and Dr. Jørgen Sorberg Petersen (Novo) as directors in the company.
The company operates as a medical research company, developing medical methodologies to address the multiple challenges affecting the TCR-based therapeutic discovery and development process, offering innovative high-throughput solutions to TCR engineering and safety screening. The company's platform technology combines three methods in the life science field -- genome editing, deep sequencing and machine learning.
Current Investors
Novo Holdings, Pureos Bioventures, Kinled Holding
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
http://www.engimmune.com
Verticals
Artificial Intelligence, Artificial Intelligence, Cloud Computing
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.